Abstract
To compare baseline characteristics and major depressive disorder (MDD)-related healthcare resource use during the 1-year post-medication initiation of patients with MDD who were initiated on selective-noradrenaline-reuptake inhibitor (SNRI) compared to selective-serotonin-reuptake inhibitor (SSRI) in Beijing. Data from the Beijing Urban Employee Basic Medical Insurance Database from July 1, 2011-December 31, 2013, were used. Patients diagnosed with MDD were identified using ICD-10th F32/F33. The first-diagnosis date in 2012 was designated as the index date. Patients were aged ≥18 years; without comorbid cancer, schizophrenia, or bipolar disorder; and with 12-months continuous enrollment. Logistic regression with stepwise-effect-selection method and multivariate analyses were performed. A total of 4769 patients were included, with 8.6% initiated on SNRI. Compared with SSRI initiators, SNRI initiators were more likely to be treated at mental than general hospitals (Odds ratio (OR) [95% confidence interval (CI)]: 1.96[1.58, 2.42]), had more MDD-related outpatient visits during the 6-month pre-index date (1.18[1.11, 1.25]), and were more likely to be treated at tier-3 hospitals (0.15[0.06, 0.41] for tier 1 vs 3; 0.50[0.36, 0.69] for tier 2 vs 3). In the year following medication initiation, few patients (0.5%) experienced MDD-related hospitalizations in either medication initiation group. The SNRI and SSRI initiators were not significantly different on MDD-related outpatient services (least-squares mean difference[95% CI] for number of outpatient visits: 0.31[-0.01, 0.64]; OR[95% CI] for having ≥2 outpatient visits: 1.04[0.82, 1.32] for SNRI vs SSRI). Chinese physicians seem more likely to choose SNRI than SSRI for the treatment of severely-ill MDD patients, as suggested by the patients’ higher likelihood of being treated at mental hospitals and having more MDD-related outpatient visits pre-medication initiation. Although SNRI initiators may be more severely-ill at medication initiation, they were not found to differ from SSRI initiators on outpatient and inpatient service use for MDD in the year following medication initiation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.